Microglia are the resident immune cells of the central nervous system (CNS). In contrast to the sparsely distributed innate immune cells in other organs, microglia form a tile-like network that covers the entire brain parenchyma. They play an essential role in removing apoptotic neurons and sculpting synaptic fields during brain development. 1, 2 Microglia, therefore, are essential for establishing and maintaining CNS networks that are critical for maximizing brain function. 3 While studies implicate microglia in the pathogenesis of neurodegenerative diseases, we argue that there is little evidence to support a destructive role for microglia in CNS disease in general, and no evidence that they play a primary role in cortical damage in multiple sclerosis (MS).
Harmful microglia: guilt by association
The most compelling evidence for microglia performing a destructive role in neurodegenerative disease is their physical association with dying cells, dystrophic neurites, and cellular debris. 2 As the innate immune cells of the CNS, this is what microglia are supposed to do: remove cellular debris and promote wound healing and tissue repair. By removing dead and dysfunctional structures, they are neuroprotective, not destructive. Why is it accepted that microglia have a beneficial role in removing cellular debris during development, but then the same function during disease is presumed to be destructive? We argue that the concept of microglia being destructive in CNS disease has never been convincingly demonstrated. How would one obtain such evidence? One approach is to investigate human disease caused by mutations in innate immune cells. Microglia can promote neurodegeneration in these diseases, but do so by loss of protection, not by a gain of destructive behavior. For example, loss-of-function mutations in the microglial protein, Trem2, lead to increased susceptibility to Alzheimer's disease (AD) and frontotemporal dementia. 4 In an AD rodent model, failure to recruit activated microglia to Aβ deposits increases disease progression and decreases life span. 5 Similar attempts to produce gain-of-destructive mutations in experimental models of neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), 6 Rett syndrome, 7 and retinitis pigmentosa 8 support loss (mostly phagocytic) of a protective role for microglia in these models. Consequently, gain-of-function mutations that activate microglia to damage the CNS have not been identified.
Do microglia play a role in cortical damage in MS?
We focus on subpial cortical demyelination for several reasons. Subpial cortical lesions are abundant, they contain few peripheral immune cells, most demyelinate cortical layers I-IV, 9 and they are generally considered to be most prominent in chronic MS brains. 10 Microglia are activated in MS cerebral cortex; they change shape and upregulate activation markers, including major histocompatibility complex (MHC) class II and CD 68. Neither activation marker is specific for microglia in cortical layers I-IV. In many postmortem MS brains, all cortical microglia, including those in myelinated cortex, have been found to be activated using these criteria. Based upon detection of oxidative enzymes and lipid peroxidation products in microglia, 11 microgliamediated oxidative stress has been proposed to cause cortical damage in MS. This is another instance of "guilt by association" as neither the mechanisms nor the targets of microglia-mediated oxidative stress have been identified. Attempts to identify oxidative injury, mitochondrial damage, and iron-related pathology in rodent models of MS have also been disappointing. 12 Oligodendrocyte progenitor cells (OPCs), which express low levels of antioxidant enzymes, 13 have been proposed as primary targets of microglia-mediated oxidative stress. Since OPC densities are increased in subpial lesions, 14 it is unlikely that microglia-mediated oxidative stress has a negative effect on cortical OPCs. In fact, microglia-mediated myelin removal during demyelination has been shown to facilitate remyelination. 15 
A possible role for B cells in cortical demyelination
There is significant interest in the possible role of B-cell follicles located in cortical meninges in causing subpial demyelination. While the presence of B-cell follicles in MS brain meninges is controversial, 16 meningeal inflammation consisting of T and B cells has been documented by several studies. 17 While the number of these immune cells is low, their detection continues to support the concept that these immune cells secrete molecules that diffuse through the pial surface and cause subpial demyelination. Our studies of MS brains, however, provide several interesting observations that question such a mechanism. First, subpial demyelination does not occur as a continuous wave from the pial surface to cortical layer IV. They often skip layer I and simultaneously demyelinate layers II-IV. These demyelination dynamics do not support a diffusible factor that activates microglia as the cause of subpial demyelination. Second, these lesions seldom progress to subcortical white matter. There is no rationale for limiting the effect of such molecules, if they exist, on microglia present only in cortical layers I-IV. Finally, it is presently impossible to distinguish a destructive role of microglia from their phagocytic role in removing myelin debris in cortical lesions.
Whether microglia have a role in cortical damage is extremely important for the MS community. If this concept is accepted, development of therapies to reduce microglial activation could have devastating consequences. Microglia are in the brain to protect it and they do so through several mechanisms. Phagocytic removal of debris is fundamental to slowing the progression of MS and other neurodegenerative diseases. Many brains in our MS autopsy cohort have lost over 30% of their volume and include significant cortical thinning. Amazingly, little cellular debris can be detected in these brains, which is indicative of the efficiency of microglia in removing cellular debris. Inhibition of microglial activation and suppression of debris removal would accelerate, not ameliorate, disease progression.
In summary, we conclude that there is no convincing evidence supporting the concept that microglia are responsible for the cortical damage in MS. Microglia respond to cortical damage, rather than causing it. Transection of cortical neuronal projections and loss of efferent inputs to the cortex have direct effects on cortical neurons and are responsible for much of the cortical damage. Finally, it is possible that a primary neurodegenerative process independent of the adaptive and innate immune systems plays a significant role in cortical damage in MS. Descriptions of cortical pathology in multiple sclerosis (MS) have existed for centuries. Charcot described grey matter 'patches' in seminal lectures in 1868, and Brownell and Hughes described cerebral plaques in a series of 22 MS cases in the 1960s, but it is only recently that significant attention has been given to cortical lesions and their correlation with clinical disease progression. 1 Current research aims to disentangle the individual contributions of different immune cells and soluble mediators, with particular attention given to the role of meningeal inflammation. At the epicentre of pathology are microglia, the resident macrophages of the central nervous system (CNS). Activated microglia are found both in early active and chronic cortical MS lesions 2 and in normal-appearing grey matter (NAGM). 3, 4 Upstream, antigen presentation by HLA-DRB1*15 appears to be a key driver of cortical pathology, 5 while downstream roles of microglia in phagocytosing debris and oxidative damage have been identified. Further complexity arises from increasingly recognized diversity in microglial phenotypes. 6 Whether the overall contribution of microglia to cortical pathology in MS is deleterious or protective remains unclear. The situation is analogous to how one would know, looking from the outside, whether policemen in a riot are adding to damage or helping to reduce it.
In this issue, van Wageningen and van Dam, and Dutta and Trapp debate the true role of microglia in MS. The 'yes' argument draws attention to the correlation between activated microglia, production of reactive oxygen species and disease severity and discusses techniques for demonstrating true causality in the future. Conversely, Dutta and Trapp argue that microglia are victims of guilt-by-association. They say that studies using microglial activation markers are non-specific and that the anatomy of subpial pathology does not fit with meningeal inflammation activating microglia. Both groups agree there is a large gap in our knowledge and that resolving this controversy is an important challenge to tackle.
So far, studies in this area have been limited by contrasting findings in mouse models of MS and postmortem human brains. Cortical demyelination is absent in most experimental autoimmune encephalomyelitis (EAE) models, whereas it is prominent in human MS. 7 Conversely, post-mortem studies provide a static view of typically late-stage disease, with small sample sizes and little mechanistic insight. Our understanding is further limited by a research bias towards MS lesions. The demyelinating lesion is the hallmark of MS, but to truly understand cortical pathology there
